Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy

Article Abstract:

Research presented concerns the dynamics of HIV infection after the use of highly active anti-retroviral therapy by HIV patients. Topics addressed include how the latent viral reservoir affects CD4 T cells and rebounding plasma viremia.

Author: Chun, Tae-Wook, Davey, Richard T. Jr., Ostrowski, Mario, Justement, J. Shawn, Engel, Delphine, Mullins, James I., Fauci, Anthony S.
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2000
Viremia, CD4 lymphocytes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes

Article Abstract:

A model of HIV virus progression in rhesus monkeys is presented, focusing on the difficulties of achieving an antibody or immunological response to HIV-1 envelope proteins. Rhesus macaques were immunized with phage-displayed epitopes and evaluated for protection levels from viral challenge.

Author: Lewis, Mark G., Chun, Tae-Wook, Justement, J. Shawn, Fauci, Anthony S., Venzon, David, Chen, Xueni, Scala, Giuseppe, Quinto, Ileana, Liu, Weimin, Cohen, Oren J., VanCott, Tom C., Iwanicki, Marcin, Greenhouse, Jack, Barry, Todd
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2001
Italy, Statistical Data Included, Diseases, AIDS vaccines, Rhesus monkey

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Effect of interleukin-2 on the pool of latently infected, resting CD4(super.+) T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

Article Abstract:

Intermittent administration of interleukin (IL)-2 with continuous highly active anti-retroviral therapy (HAART) may lead to a substantial reduction in the pool of resting CD4(super.+) T cells containing replication-competent HIV. In a recent study it was found that virus could not be isolated from the peripheral blood CD4(super.+) T cells in three patients receiving IL-2 plus HAART. The size of the pool of resting CD4(super.+) T cells containing replication-competent HIV in the blood of patients receiving intermittent IL-2 plus HAART was significantly lower than that of patients getting only HAART.

Author: Corey, Lawrence, Kovacs, Joseph A., Lane, H. Clifford, Chun, Tae-Wook, Engel, Delphine, Fauci, Anthony S., Davey, Richard T., Jr., Metcalf, Julia A., Park, Sohee, Hallahan, Claire W., Dybul, Mark, Mizell, Stehanie B., Fishette, Maria, Mican, JoAnn M., Berrey, M. Michelle
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 1999
Health aspects, Drug therapy, Interleukin-2

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, United States, HIV infection, HIV infections, Highly active antiretroviral therapy, Physiological aspects, HIV (Viruses), HIV
Similar abstracts:
  • Abstracts: Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the nutrition for healthy living cohort
  • Abstracts: Latent infection of CD4(super.+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
  • Abstracts: Gamma secretase-medicated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Activin to the rescue for overexcited neurons
  • Abstracts: The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Transcriptional regulation of cellular transformation
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.